格隆汇1月5日丨复旦张江(688505.SH)公布，公司于2026年1月5日收到股东杨宗孟先生发来的《关于股 份减持计划实施情况的告知函》，杨宗孟先生于2025年11月26日至2026年1月5日通过集中竞价交易的方 式累计减持公司股份241.69万股，其持有公司股份由64,009,773股减少至61,592,865股，占公司总股本的 比例由6.18%降至5.94%。本次权益变动触及1%的整数倍。 ...

复旦张江公告称，2025年11月26日至2026年1月5日，股东杨宗孟通过集中竞价交易累计减持241.6908万 股。其持股由6400.9773万股降至6159.2865万股，占总股本比例由6.18%降至5.94%。此次权益变动触及 1%整数倍，且该减持为履行此前计划，截至公告披露日，减持计划尚未实施完毕。公司无控股股东和 实控人，此次减持不影响控制权，不涉及披露权益变动报告书。 ...

認購結構性存款產品 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 須予披露的交易 認購浦發銀行結構性存款產品 本公司與浦發銀行訂立之結構性存款產品協議的主要條款載列如下： | 年化收益率： | 協議 | | 本金 | | 收益率範圍 | | --- | --- | --- | --- | --- | --- | | | 浦發銀行結構性存款產品協議 | 人民幣 | 2.10 | 億元 | 0.70%-1.90% | 在浦發銀行結構性存款產品協議項下，實際年化收益率如下情況計算： | | 實際年化 | | --- | --- | | 觀察價格區間 | 收益率 | | 觀察價格＜期初價格*92.77% | 0.70% | | 期初價格*92.77%≤觀察價格＜期初價格*107.64% | 1.70% | | 觀察價格≥期初價格*107.64% | 1.90% | 近日，本公司與浦發銀行訂立浦發銀行結構性存款產品協議，同意以日常營運產生的自有 閑置資金向浦發銀 ...

須予披露的交易 認購浦發銀行結構性存款產品 認購結構性存款產品 近日，本公司與浦發銀行訂立浦發銀行結構性存款產品協議，同意以日常營運產生的自有 閑置資金向浦發銀行認購總金額為人民幣 2.10 億元的結構性存款產品。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 上市規則的涵義 在訂立浦發銀行結構性存款產品協議時，就浦發銀行結構性存款產品協議項下產品的認購 金額而言，一項或多項適用百分比率（定義見上市規則第14.07條）超過5%但均低於25%， 故根據上市規則第 14 章，该交易構成本公司之須予披露的交易，須遵守上市規則第 14 章有 關申報及公告之規定，惟獲豁免遵守獨立股東批准之規定。 概述 近日，本公司與浦發銀行訂立浦發銀行結構性存款產品協議，同意以日常營運產生的自有閑 置資金向浦發銀行認購金額為人民幣 2.10 億元的結構性存款產品。 - 1 - 浦發銀行結構性存款產品協議 本公司與浦發銀行訂立之結構性存款產品協議的主要條款載列如下： | 年化收益 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 公司名稱: 上海復旦張江生物醫藥股份有限公司 呈交日期: 2026年1月4日 | 2. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 688505 | 說明 | | A股（上海證券交易所科創板） | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 710,572,100 | RMB | | 0.1 | RMB | | 71,057,210 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 710,572,100 | RMB | | 0.1 | RMB | | 71,057,210 | 第 1 頁 共 11 頁 v 1. ...

Core Viewpoint - Fudan Zhangjiang (01349.HK) has received approval from the National Medical Products Administration for the clinical trial application of FZ-P001 sodium injection, aimed at visualizing malignant lesions in known or suspected lung cancer patients during surgery [1] Group 1: Product Development - FZ-P001 sodium injection is a new class of chemical drug independently developed by the company, characterized as an innovative photosensitizer [1] - The active component of FZ-P001 sodium is a molecule formed by the coupling of a folate receptor-targeting small molecule and a phthalocyanine photosensitizer [1] - The drug targets malignant tumor tissues that highly express folate receptor alpha (FRα) and provides fluorescence imaging in the near-infrared range [1] Group 2: Clinical Application - The company plans to utilize FZ-P001 sodium for developing intraoperative fluorescence guidance technology to indicate the residual malignant tumor tissue and margin status during surgeries [1] - The aim is to enhance the surgical resection effectiveness for related solid tumors, such as ovarian cancer and lung cancer [1] - This innovation seeks to provide a solution for precise navigation in tumor surgery, combining molecular targeting specificity with multidimensional biological sensing [1]

Core Viewpoint - Fudan Zhangjiang (01349) has received approval from the National Medical Products Administration for the clinical trial application of FZ-P001 sodium injection, aimed at visualizing malignant lesions in known or suspected lung cancer patients during surgery [1] Group 1: Product Development - FZ-P001 sodium injection is a new class of chemical drug developed by the company, characterized as an innovative photosensitizer [1] - The active ingredient is a molecule that combines folate receptor-targeting small molecules with phthalocyanine-type photosensitizers, specifically targeting malignant tumor tissues that express high levels of folate receptor alpha (FRα) [1] - The company plans to utilize this drug to develop intraoperative fluorescence guidance technology to indicate the residual malignant tumor tissue and margin status during surgeries [1] Group 2: Clinical Trials - The application to the National Medical Products Administration also includes a registration for a Phase I clinical trial for the drug's use in visualizing malignant lesions during ovarian cancer surgery [1] - The company intends to conduct a Phase II clinical trial application for new indications of the drug [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 - 1 - 提示性公告 注射用 FZ-P001 鈉 用於已知或疑似肺癌患者術中惡性病變可視化 獲得藥物臨床試驗申請受理通知書 本公告乃由上海復旦張江生物醫藥股份有限公司（「本公司」）自願作出。 本公司之董事會（「董事會」）欣然公佈，本公司收到國家藥品監督管理局（「國家 藥監局」）核准簽發的《受理通知書》，注射用 FZ-P001 鈉（「該藥物」）用於已知 或疑似肺癌患者術中惡性病變可視化的 II 期臨床試驗申請獲得受理，現將相關情況公 告如下： 關於該藥物 藥物名稱： 注射用 FZ-P001 鈉 註冊分類： 化學藥品 1 類 申請事項： 境內生產藥品註冊臨床試驗 受 理 號： CXHL2501449 申 請 人： 上海復旦張江生物醫藥股份有限公司 審批結論： 根據《中華人民共和國行政許可法》第三十二條的規定，經審查，決 定予以受理。 原發性支氣管肺癌簡稱肺癌，是我國及世界各國發病率和死亡率較高的惡性腫瘤之一。 ...

Group 1 - 德方纳米 plans annual equipment maintenance to ensure efficient and stable operation, starting January 1, 2026, for one month, with no significant impact on 2026 performance [1] - 达意隆's subsidiary Tianjin Baolong faces a significant decline in OEM orders due to strategic adjustments from core customers, leading to plans to shut down production lines [2] - 天威视讯's subsidiary plans to transfer project assets for 604.3 million yuan to a related party, constituting a related transaction [3] Group 2 - 金龙羽 intends to sign a strategic cooperation framework agreement with an investment institution to establish an industrial merger fund with a planned scale of 1.5 billion yuan [4] - 紫光国微's subsidiary plans to establish a new company with multiple partners, including a subsidiary of CATL, with a registered capital of 300 million yuan [5] - 信隆健康's major shareholder plans to reduce its stake by up to 1% through trading [6] Group 3 - 龙建股份 wins a 612 million yuan EPC contract for a project, which represents approximately 3.27% of the company's audited revenue for 2024 [7] - 复旦张江 receives acceptance for a clinical trial application for a drug aimed at visualizing malignant lesions in lung cancer patients [9] - 博实股份's major shareholder plans to reduce its stake by up to 2.93% [10] Group 4 - 百纳千成 plans to acquire 100% of Zhonglian Century's shares to expand its marketing business and digital advertising solutions [11] - 天铁科技's major shareholder is under criminal detention, but the investigation is unrelated to the company's operations [12] - 海看股份's shareholder plans to reduce its stake by up to 3.6% [13] Group 5 - 智光电气's subsidiary signs a procurement contract worth 148 million yuan for a high-voltage energy storage system [14] - 西藏矿业's attempt to transfer 100% of a subsidiary's equity has not attracted qualified buyers, leading to automatic withdrawal from the trading platform [15] - 英诺激光's major shareholder plans to reduce its stake by up to 3% [16] Group 6 - 福鞍股份's major shareholder plans to reduce its stake by up to 3% [17] - 白云山 receives a drug registration certificate for a rabies vaccine [18] - 华电科工 signs a contract worth approximately 265 million yuan for a power plant project [19] Group 7 - 康弘药业 receives a drug registration certificate for a medication used to treat schizophrenia [20] - 西菱动力's actual controller plans to reduce their stake by 2% [21] - 海希通讯's actual controller plans to reduce their stake by 0.48% [22] Group 8 - 海南机场 plans to transfer 90% of a subsidiary's equity for approximately 500 million yuan, expecting a profit of about 200 million yuan from the transaction [23] - 森远股份 signs a contract for a computing cluster integration project worth 26.78 million yuan [24] - 丽珠集团's subsidiary receives acceptance for a drug registration application for a new treatment for psoriasis [25] Group 9 - 郑州银行 plans to acquire a village bank and convert it into a branch [26] - 方正证券 announces a cash dividend distribution plan for the third quarter of 2025 [27] - 金陵体育 announces a cash dividend distribution plan for the first three quarters of 2025 [29] Group 10 - 紫金银行 announces a mid-term profit distribution plan for 2025 [30] - *ST建艺's major shareholder waives 1.4 billion yuan in debt and donates 400 million yuan to support the company [31] - 万朗磁塑's major shareholder plans to reduce their stake by up to 3% [32] Group 11 - 艾力斯's core product is included in a list of potential breakthrough therapies for lung cancer [33] - 富创精密's shareholder plans to transfer 918.63 million shares [34] - 东阳光's subsidiary plans to increase capital and introduce investors [35] Group 12 - 侨银股份 plans to acquire a 16.67% partnership in a venture capital fund [36] - 尤夫股份 receives a government subsidy of 4.04 million yuan for a technical improvement project [37] - 倍轻松 and its actual controller are under investigation for information disclosure violations [38] Group 13 - 万润新能 plans to reduce production on some lines for maintenance, expecting a reduction of 5,000 to 20,000 tons in lithium iron phosphate output [39]

Group 1 - The core point of the article is that Fudan Zhangjiang (688505) has received approval from the National Medical Products Administration for the clinical trial application of FZ-P001 sodium for visualizing malignant lesions in known or suspected lung cancer patients during surgery [1] Group 2 - The clinical trial is categorized as a Phase II trial, indicating that it is in the second stage of testing for safety and efficacy [1]